The effects of pantethine on fatty liver and fat distribution

Y Osono ¹, N Hirose, K Nakajima, Y Hata

Affiliations expand

PMID: 11425046 DOI: 10.5551/jat1994.7.55

Abstract

Although the prognosis of fatty liver depends on its causes, we feel from our clinical experience that fatty liver with hypertriglyceridemia has a good prognosis and responds well to treatment. In this study, 600 mg/day of pantethine was administered to 16 outpatients with fatty liver and hypertriglyceridemia for six months or longer to examine whether the drug improved fatty liver using abdominal plain computed tomography (CT). Nine of the 16-pantethine patients were no longer diagnosed as having fatty liver after the study period. An chi2 test indicated the significant disappearance of fatty liver. At the same time, the visceral fat calculated from the CT image passing the umbilical region was also significantly reduced. On the contrary, the subcutaneous fat area tended to increase, so the ratio of the visceral-to-subcutaneous fat area was reduced significantly. This indicates triglycerides may be pooled in the body as hepato-visceral fat and subcutaneous fat, and that pantethine may transfer fat from the liver and viscera to the subcutaneous tissue. This suggests that visceral fat deposition and fatty liver occurring with hypertriglyceridemia may have a common basis, probably excessive matrixes, and that pantethine may simultaneously improve the two conditions.

PubMed Disclaimer

Similar articles

Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease.

Eguchi Y, Eguchi T, Mizuta T, Ide Y, Yasutake T, Iwakiri R, Hisatomi A, Ozaki I, Yamamoto K, Kitajima Y, Kawaguchi Y, Kuroki S, Ono N.

J Gastroenterol. 2006 May;41(5):462-9. doi: 10.1007/s00535-006-1790-5.

PMID: 16799888

Effects of dietary pantethine levels on contents of fatty acids and thiobarbituric acid reactive substances in the liver of rats orally administered varying amounts of autoxidized linoleate.

Hiramatsu N, Kishida T, Hamano T, Natake M.

J Nutr Sci Vitaminol (Tokyo). 1991 Feb;37(1):73-87. doi: 10.3177/jnsv.37.73.

PMID: 1880633

A novel method of measuring intra-abdominal fat volume using helical computed tomography.

Kobayashi J, Tadokoro N, Watanabe M, Shinomiya M.

Int J Obes Relat Metab Disord. 2002 Mar;26(3):398-402. doi:

10.1038/sj.ijo.0801921.

PMID: 11896496

Pantethine inhibits cholesterol and fatty acid syntheses and stimulates carbon dioxide formation in isolated rat hepatocytes.

Cighetti G, Del Puppo M, Paroni R, Fiorica E, Galli Kienle M.

J Lipid Res. 1987 Feb;28(2):152-61.

PMID: 3106549

Preclinical and clinical studies with cysteamine and pantethine related to the central nervous system.

Vécsei L, Widerlöv E.

Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(6):835-62. doi: 10.1016/0278-5846(90)90072-o.

PMID: 2277850 Review.

See all similar articles

Cited by

Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease.

Thomas EL, Brynes AE, Hamilton G, Patel N, Spong A, Goldin RD, Frost G, Bell JD, Taylor-Robinson SD.

World J Gastroenterol. 2006 Sep 28;12(36):5813-9. doi:

10.3748/wjg.v12.i36.5813.

PMID: 17007047 Free PMC article. Clinical Trial.

Publication types

Clinical Trial

MeSH terms

Abdomen

Aged

Case-Control Studies

Fatty Liver / drug therapy*

Fatty Liver / metabolism

Female

Humans

Liver / anatomy & histology

Liver / drug effects

Male

Middle Aged

Pantetheine / analogs & derivatives*

Pantetheine / therapeutic use*

Tomography, X-Ray Computed

Substances

Pantetheine

pantethine

Related information

PubChem Compound (MeSH Keyword)

LinkOut - more resources

Other Literature Sources

The Lens - Patent Citations Database